Stefanie Kreamer
Family Medicine · Quincy, FLNPI 1073956108
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 403 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,410 and has fallen 63.2% since, to $519 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 403 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Pfizer$879
- Boehringer Ingelheim$806
- Lilly USA, LLC$469
- AstraZeneca$434
- AbbVie$361
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,956100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 79 | $1,399 |
| Pfizer | 57 | $879 |
| Boehringer Ingelheim | 40 | $806 |
| Lilly USA, LLC | 35 | $469 |
| AstraZeneca | 21 | $434 |
| AbbVie(2 entities) | 24 | $361 |
| Sanofi-aventis U.S. LLC | 19 | $355 |
| GSK | 21 | $267 |
| Abbott | 12 | $264 |
| Merck | 15 | $225 |
| Bayer | 10 | $163 |
| Supernus Pharmaceuticals, Inc. | 1 | $154 |
| Teva Pharmaceuticals USA, Inc. | 6 | $107 |
| Dexcom, Inc. | 4 | $103 |
| Johnson & Johnson | 6 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $91 |
| Amarin Pharma, Inc. | 5 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $78 |
| Sanofi Pasteur Inc. | 5 | $75 |
| Phathom Pharmaceuticals, Inc. | 4 | $73 |
| Amgen | 5 | $69 |
| Astellas Pharma US Inc | 3 | $56 |
| Novartis | 3 | $47 |
| Organon | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Exact Sciences | 2 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $27 |
| PBG Puerto Rico LLC | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Global Blood Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,962 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 232 | $302,404 |
| EliquisApixaban | 122 | $137,844 |
| OzempicSemaglutide | 81 | $113,759 |
| JanuviaSitagliptin Phosphate | 87 | $103,939 |
| MounjaroTirzepatide | 57 | $76,518 |
| TrulicityDulaglutide | 45 | $61,267 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 44 | $54,579 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $49,091 |
| FarxigaDapagliflozin Propanediol | 38 | $48,134 |
| MyrbetriqMirabegron | 51 | $41,856 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 37 | $41,188 |
| RybelsusSemaglutide | 13 | $36,578 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $24,368 |
| UbrelvyUbrogepant | 20 | $23,227 |
| XareltoRivaroxaban | 17 | $22,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $806 | $313,509245 claims |
| Novo NordiskOzempic, Rybelsus | $1,399 | $150,33694 claims |
| MerckJanuvia, Janumet Xr | $225 | $145,127124 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25 | $469 | $142,924121 claims |
| PfizerEliquis | $879 | $137,844122 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $267 | $78,86585 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $434 | $71,48579 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $355 | $54,57944 claims |
| AbbVieUbrelvy, Linzess | $361 | $43,18941 claims |
| Astellas Pharma US IncMyrbetriq | $56 | $41,85651 claims |
| Johnson & JohnsonXarelto | $97 | $22,86517 claims |
| NovartisEntresto | $47 | $22,78715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Quincy
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.